Non-viral delivery of cDNA encoding for sTRAIL in combination with HDAC inhibitors results in in vitro and in vivo anti-tumor efficacy in HCC with minimal toxicity to human hepatocytes. This evidence concerns the gene HDAC9 and hepatocellular carcinoma.